---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-039705"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:41:27.215146+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BridgeBio reports positive Phase 3 results for encaleret in ADH1; 76% met primary endpoint

## Summary
- 76% of encaleret-treated patients achieved both serum and urine calcium targets vs 4% on conventional therapy (p<0.0001).
- 91% on encaleret achieved intact PTH above lower limit vs 7% on conventional therapy (p<0.0001).
- Encaleret was well-tolerated with no discontinuations related to study drug.
- NDA submission to FDA planned H1 2026; EMA submission to follow.
- BridgeBio plans to initiate registrational trials in pediatric ADH1 and chronic hypoparathyroidism in 2026.

## SEC filing metadata
- accession: 0001140361-25-039705
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/0001140361-25-039705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036125039705/ef20057894_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-039705
- JSON: https://secwatch.observer/filing/0001140361-25-039705.json
- Plain text: https://secwatch.observer/filing/0001140361-25-039705.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.